)
InMode (INMD) investor relations material
InMode 25th Annual Needham Virtual Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Financial performance and outlook
Achieved approximately 5% year-over-year growth in Q1, driven mainly by the launch of the Picofy picolaser in the US market.
Guidance for 2026 remains similar to 2025, with no expectation of significant growth unless Q2 performance exceeds expectations.
Gross margin declined from 85% to 75%, impacted by increased costs, competitive pricing, and a higher mix of third-party laser products.
Operating profit and net profit are under pressure due to higher costs and industry competition, but the company remains cash positive.
Share buybacks continue, with 10% of shares repurchased annually to optimize capital allocation and avoid dividend tax.
Product portfolio and innovation
Introduced Picofy picolaser in the US, with plans to expand to Europe and Asia in Q2; gross margin on this product is lower due to third-party sourcing.
Solaria CO2 laser and ApexRF Urology system launched in 2025, with steady but limited sales expected due to market saturation and regulatory constraints.
Morpheus8 with Erbium laser capability is pending FDA submission, targeted for market launch in Q4.
Ongoing studies for new indications, including overactive bladder and erectile dysfunction, with potential market entry for these applications after 2027.
Market dynamics and geographic expansion
No significant momentum observed in the aesthetic market; disposable sales remain flat despite an expanding installed base.
Market is not considered saturated, with an estimated 150,000 potential clinics in the US and significant opportunities in international markets.
Direct sales focus in 20 countries generates 80% of revenue; new subsidiaries are established selectively, with recent expansion in Thailand, Argentina, and plans for China.
- Manufacturing and logistics face disruption, but strategic buybacks and global expansion continue.INMD
Oppenheimer 36th Annual Healthcare MedTech & Services Conference16 Mar 2026 - Flat top line expected in 2026, with new products and restructuring to drive future recovery.INMD
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Q4 revenue up 6% to $103.9M, FY sales down 6%, 2026 stable with new launches and strong cash.INMD
Q4 202510 Feb 2026 - Q2 revenue fell 36.5% to $86.4M; guidance cut, but new launches and buybacks support outlook.INMD
Q2 20242 Feb 2026 - Strong innovation and global expansion offset U.S. softness; M&A remains top capital priority.INMD
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Product refresh, robust margins, and innovation drive growth amid macro headwinds and financing shifts.INMD
Jefferies Global Healthcare Conference31 Jan 2026 - 2024 buyback, international expansion, and new product upgrades drive long-term growth focus.INMD
Baird's 2024 Global Healthcare Conference21 Jan 2026 - Q3 2024 revenue rose to $130.2M, but margins and guidance declined amid macro headwinds.INMD
Q3 202417 Jan 2026 - Stable but soft market, ongoing investment, and new segments drive future growth opportunities.INMD
UBS Global Healthcare Conference 202414 Jan 2026
Next InMode earnings date
Next InMode earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage